Skip to Content
Merck
  • Influence of coadministration of artemether and lumefantrine on selected plasma biochemical and erythrocyte oxidative stress indices in female Wistar rats.

Influence of coadministration of artemether and lumefantrine on selected plasma biochemical and erythrocyte oxidative stress indices in female Wistar rats.

Human & experimental toxicology (2012-11-17)
A O Abolaji, M U Eteng, O Omonua, Y Adenrele
ABSTRACT

Among the artemisinin-based combination therapy (ACT) regimens, artemisinin derivative, artemether in combination with lumefantrine (artemether-lumefantrine, AL) has achieved excellent results in the fight against malarial scourge. In this study, we evaluated the toxic potential of these drugs at the therapeutic doses in female Wistar rats. Animals were randomly divided into four groups: those administered 1% Tween 80 (control), those administered artemether (4 mg/kg body weight), those administered lumefantrine (24 mg/kg body weight), and those coadministered artemether (4 mg/kg body weight) and lumefantrine (24 mg/kg body weight). The drugs were orally administered twice daily for 3 days by gastric intubation after which selected plasma biochemical indices, and erythrocytes antioxidant defence and lipid peroxidation markers were evaluated. Coadministration of artemether and lumefantrine raised liver and renal function markers and increased atherogenic index. While reduced glutathione, glucose-6-phosphate dehydrogenase (G6PD) and catalase activities were reduced, glutathione peroxidase and glutathione-s-transferase activities increased in all the treated groups compared to the control group. The drugs caused significant (p < 0.05) elevation of malondialdehyde (MDA) levels compared to the control group. These results imply that coadministration of artemether and lumefantrine may increase the risks of atherosclerosis as well as liver and renal function impairments in the users. In addition, the drugs may also promote oxidative stress in the erythrocytes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type VII, ammonium sulfate suspension, ≥200 units/mg protein
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type IX, lyophilized powder, 200-400 units/mg protein (modified Warburg-Christian)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type XV, lyophilized powder, 200-400 units/mg protein (modified Warburg-Christian)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, recombinant, expressed in E. coli, ammonium sulfate suspension, ≥550 units/mg protein (biuret)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, lyophilized powder, >= 550 units/mg protein (biuret)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, Type XXIII, ammonium sulfate suspension, 550-1,100 units/mg protein (biuret), ≥2.0 mg/mL Biuret
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, recombinant, expressed in E. coli, lyophilized powder, ≥550 units/mg protein (biuret)
Sigma-Aldrich
Lumefantrine